Skip to search formSkip to main contentSkip to account menu

Factor Xa inhibitors

Known as: Inhibitors, Factor Xa 
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
National Institutes of Health

Related topics

Related topics

33 relations

Narrower (27)

Amblyomin-X protein, Amblyomma cajennenseAntithrombin IIIBMS 269223DPC 602
Factor Xa Inhibitor [EPC]In Bloodaspects of radiation effectschemical synthesis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Andexanet alfa for the reversal of factor Xa inhibitors
ABSTRACT Introduction: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa… 
2017
2017
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.
Factor Xa (fXa)-inhibitors are as effective and safer than vitamin-K-antagonists (VKA) in the treatment of venous thromboembolism… 
Review
2011
Review
2011
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation
Purpose of review To review the large phase 3 clinical trials that compare direct thrombin or factor Xa inhibitors with dose… 
2011
2011
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?
The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and… 
2010
2010
Facts and artefacts of coagulation assays for factor Xa inhibitors
Direct factor Xa inhibitors are among the compounds at the forefront of clinical development for the prevention and treatment of… 
Review
2009
Review
2009
Factor Xa inhibitors
Summary Oral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest… 
Review
2009
Review
2009
Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and… 
Review
2004
Review
2004
Clinical and Experimental Experience with Factor Xa Inhibitors
Cardiovascular disease is the major cause of mortality in the industrial world today. We are constantly moving towards new and… 
Review
2004
Review
2004
Evolving Concepts in the Treatment of Venous Thromboembolism: The Role of Factor Xa Inhibitors
Anticoagulation is an essential component of the care of patients with venous thromboembolism (VTE). Traditional anticoagulants… 
Review
2001
Review
2001
Discovery of transition state factor Xa inhibitors as potential anticoagulant agents.
Factor Xa is an attractive biological target in the discovery and development of either parenteral or orally active anticoagulant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)